Vera Therapeutics Inc (VERA)
41.38
-0.56
(-1.34%)
USD |
NASDAQ |
May 17, 16:00
41.38
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics SG&A Expense (Quarterly): 7.912M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.912M |
| December 31, 2023 | 6.243M |
| September 30, 2023 | 5.656M |
| June 30, 2023 | 5.739M |
| March 31, 2023 | 6.15M |
| December 31, 2022 | 6.905M |
| September 30, 2022 | 5.588M |
| June 30, 2022 | 4.945M |
| March 31, 2022 | 4.472M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.832M |
| September 30, 2021 | 3.688M |
| June 30, 2021 | 2.614M |
| March 31, 2021 | 1.784M |
| December 31, 2020 | 1.136M |
| September 30, 2020 | 0.652M |
| June 30, 2020 | 1.219M |
| March 31, 2020 | 1.032M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.652M
Minimum
Sep 2020
7.912M
Maximum
Mar 2024
4.092M
Average
4.472M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 342.70M |
| Alpine Immune Sciences Inc | 7.271M |
| Fate Therapeutics Inc | 20.86M |
| Mersana Therapeutics Inc | 11.56M |
| Equillium Inc | 3.737M |